Aeglea BioTherapeutics Inc (AGLE)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

901 S. MOPAC EXPRESSWAY, STE. 250 AUSTIN, TX 78746

Aeglea BioTherapeutics, Inc. operates as a biotechnology company. The Company focuses on developing enzyme-based therapeutics in the field of amino acid metabolism. Aeglea BioTherapeutics develops treatments for inborn errors of metaboli® and cancer.

Data based on most recent fiscal year report
Market Cap159.411 Million Shares Outstanding16.64 Million Avg Volume111.269 Thousand
1-Yr BETA vs S&P TR1.021 Current Ratio9.77 Quick Ratio9.77
View SEC Filings from AGLE instead.
Q2 2019 All Institutions Hedge Funds 1
To trade AGLE now:
Filers who had this stock in their top 10: 2 0 (0.0%)
13F Filers holding this stock: 77 20 (2.07%)
Aggregate 13F shares on 06/30/2019: 19.692 Million 10.541 Million
Aggregate 13F shares on 03/31/2019: 19.749 Million 10.126 Million
Percent change: -0.29% 4.10%
Funds creating new positions: 16 3
Funds Adding to an existing position: 35 8
Funds closing out their position: 8 1
Funds reducing their position: 9 2
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AGLE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

18.3 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

QUINN ANTHONY G. PRESIDENT & CEO

  • Officer
  • Director
371,908 2019-10-04 7

SHANAFELT ARMEN

  • Director
  • 10% Owner
0 2019-10-01 1

LAWLIS V BRYAN

  • Director
23,590 2019-09-17 1

MAHATME SANDESH EVP, CFO & CBO

  • Officer
42,191 2019-08-21 1

COX RUSSELL J.

  • Director
0 2019-06-10 1

BRUHN SUZANNE LOUISE

  • Director
0 2019-06-07 1

MAGOVCEVIC IVANA

  • Director
0 2019-06-07 1

NOVARTIS BIOVENTURES LTD

NOVARTIS AG

  • 10% Owner
1,769,641 2019-05-28 0

LILLY ELI & CO

  • 10% Owner
0 2019-03-11 0

SLOAN LESLIE CHIEF OPERATING OFFICER

  • Officer
0 2019-03-06 2

YORK CHARLES N II CHIEF FINANCIAL OFFICER AND VP

  • Officer
0 2019-02-28 1

SCHUCHART AARON CHIEF BUSINESS OFFICER

  • Officer
0 2019-02-28 1

WOOLDRIDGE JAMES CHIEF MEDICAL OFFICER

  • Officer
0 2019-02-28 1

GEORGIOU GEORGE

  • Director
175,861 2018-08-13 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

ISALY SAMUEL D

  • Director
941,000 2017-12-08 0

TYLER JOSEPH E VP, MANUFACTURING

  • Officer
0 2017-08-22 0

ROWLINSON SCOTT W VP, RESEARCH

  • Officer
0 2017-08-22 0

LOWE DAVID GEORGE CEO AND PRESIDENT

  • Officer
  • Director
0 2017-03-20 0

HEBEL HENRY VP, PRODUCT DEVELOPMENT

  • Officer
0 2017-03-20 0

ROJAS-CARO SANDRA CHIEF MEDICAL OFFICER

  • Officer
0 2016-05-17 0

LILLY ELI & CO

LILLY VENTURES FUND I LLC

SHANAFELT ARMEN

  • 10% Owner
2,068,543 2016-04-12 0

LILLY VENTURES FUND I LLC

SHANAFELT ARMEN

TORRES S. EDWARD

  • Director
  • 10% Owner
57,619 2016-04-06 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

QUINN ANTHONY G. - Director - Officer PRESIDENT & CEO

2019-10-04 M 662 $5.46 a 354,305 371,908.00 direct

QUINN ANTHONY G. - Director - Officer PRESIDENT & CEO

2019-10-04 M 662 d 0 371,908.00 direct

QUINN ANTHONY G. - Director - Officer PRESIDENT & CEO

2019-10-04 M 17,603 $6.31 a 371,908 371,908.00 direct

QUINN ANTHONY G. - Director - Officer PRESIDENT & CEO

2019-10-04 M 17,603 d 119,914 371,908.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments